Levodopa availability improves with progression of Parkinson's disease.

Journal of Neurology
Dirk WoitallaThomas Müller

Abstract

Previous pharmacokinetic trials with standard levodopa formulations showed a different behaviour of levodopa degradation in plasma of patients with Parkinson's disease (PD) in various stages. To investigate associations between levodopa plasma levels in relation to the scored intensity of PD. We administered water soluble 100 mg levodopa and 25 mg benserazide to 50 PD patients, taken off medication for at least 12 hours, and assessed the levodopa plasma concentrations during an 180 minutes period under standardised conditions. The computed area under the curve (AUC) values of levodopa plasma levels were significant higher in advanced PD patients. PD rating scores significantly correlated to the AUC outcomes and the maximum levodopa plasma concentration. Levodopa availability improves with progression of PD. This may result from deteriorated peripheral activity of levodopa metabolising enzymes or an increasing enteric dysfunction with subsequent better duodenal levodopa absorption or both.

References

Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Jan 1, 1991·European Journal of Clinical Pharmacology·M ContinA Baruzzi
Apr 1, 1991·British Journal of Clinical Pharmacology·D R RobertsonC F George
May 1, 1967·Neurology·M M Hoehn, M D Yahr
Jan 1, 1996·Journal of Neural Transmission·M MurataI Kanazawa
Jan 1, 1997·European Neurology·M Murata, I Kanazawa
Dec 17, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·I SoykanR W McCallum
Oct 16, 1999·Neurology·P CummingA Gjedde
May 19, 2000·Parkinsonism & Related Disorders·T MüllerW Kuhn
Aug 2, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·B HöglC Trenkwalder
Mar 21, 2002·Acta Neurologica Scandinavica·D A M C van de VijverA de Boer
Oct 22, 2002·Expert Opinion on Pharmacotherapy·Thomas Müller
Jan 28, 2003·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·G ArabiaA Quattrone
Jul 10, 2003·Lancet Neurology·Ronald F Pfeiffer
Jan 14, 2004·Neurology·Peter A LeWitt, Dag Nyholm
Feb 10, 2004·Journal of Neural Transmission·H PrzuntekP Riederer
Mar 24, 2004·Parkinsonism & Related Disorders·Nicolas SimonFrançois Viallet

❮ Previous
Next ❯

Citations

Dec 24, 2009·Cardiovascular Psychiatry and Neurology·Thomas Müller
Aug 9, 2012·Journal of Neuroinflammation·Valerio PisaniAntonio Pisani
Apr 14, 2010·Expert Opinion on Drug Metabolism & Toxicology·Nelida FernandezMatilde Sierra
Jan 26, 2010·Expert Opinion on Drug Delivery·Ndidi NgwulukaDinesh Naidoo
Apr 13, 2011·Expert Opinion on Drug Metabolism & Toxicology·Thomas Müller
Jun 25, 2010·Expert Opinion on Drug Metabolism & Toxicology·Thomas Müller
Nov 18, 2015·Journal of Neural Transmission·Thomas MüllerManfred Gerlach
Jul 27, 2007·Biopharmaceutics & Drug Disposition·Sonja KrösserAndreas Kovar
Jun 12, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Thomas MüllerChristoph Erdmann
May 9, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Thomas Müller, Wilfried Kuhn
May 29, 2008·Expert Review of Neurotherapeutics·Thomas Müller

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.